Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996842 | 1.00 | HTR3A (0.39) | HTR3AFLT3CHRNB2CHRNA4 | |
| SCHEMBL5002582 | 0.79 | HTR3A (0.36) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL5002581 | 0.79 | HTR3A (0.36) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL4991806 | 0.73 | HTR3E (0.39) | HTR3A | |
| SCHEMBL4991818 | 0.73 | HTR3E (0.39) | HTR3A | |
| SCHEMBL4201115 | 0.66 | NTMT1 (0.42) | — | |
| SCHEMBL7063490 | 0.64 | CHRNA7 (0.72) | HTR3A | |
| SCHEMBL5110038 | 0.63 | HTR3A (0.46) | HTR3A | |
| SCHEMBL4985407 | 0.63 | HTR3A (0.48) | HTR3ACHRNB2CHRNA4 | |
| SCHEMBL4985415 | 0.63 | HTR3A (0.48) | HTR3ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188518-A1 | 5-Substituted Imidazoles | ASTRA ZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| EP-1687302-A1 | 5-SUBSTITUTED IMIDAZOLES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049611-A1 | 5-SUBSTITUTED IMIDAZOLES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188518-A1 | 5-Substituted Imidazoles | GABRA5, GRIN2C, GABRE | HTR3A 572/4885FLT3 747/4885CHRNB2 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.